Clinical evidence from 2024 meta-analysis research establishes three key principles for magnesium use in hypertension management. First, supplementation at doses of 400 mg daily or higher, continued for at least 12 weeks, reduces systolic blood pressure by 6.38 mmHg and diastolic pressure by 3.71 mmHg. Second, the greatest therapeutic benefit occurs in patients with metabolic disorders and documented baseline magnesium deficiency, suggesting targeted supplementation strategies may optimize outcomes.
Third, and critically, magnesium supplementation should function as a complementary intervention within comprehensive cardiovascular care rather than as a replacement for established antihypertensive medications. This distinction is essential for clinical practice: while magnesium contributes meaningfully to blood pressure reduction, it does not substitute for pharmacological or lifestyle interventions in hypertension management.
Clinicians should assess magnesium status in hypertensive patients, particularly those with concurrent metabolic conditions, and integrate supplementation into multimodal treatment approaches.
Read the full article on GMJ Newsroom.
Was this article helpful?
